Plavix
Product Images NDC 21695-665

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 21695-665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (1086a7b4 B89b 4bee 8120 5f752626c046 01)

Chemical structure diagram of clopidogrel bisulfate, the active ingredient in Plavix, showing the molecular arrangement including a thiophene ring, chlorophenyl group, and methyl ester functionality with associated sulfuric acid (H2SO4).*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 02)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two curves show outcomes for placebo plus aspirin versus Plavix plus aspirin, indicating lower event rates with Plavix plus aspirin during the study period. Statistical significance is noted with P=0.00009.*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 03)

A forest plot chart showing percent events comparing PLAVIX (+aspirin) versus placebo (+aspirin) across various baseline characteristics and concomitant medications or therapies. The chart presents hazard ratios with 95% confidence intervals indicating the comparative effectiveness between PLAVIX and placebo in different subgroups defined by diagnosis, age, gender, race, cardiac enzyme levels, diabetes status, previous medical history, and concurrent treatments.*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 04)

A line graph comparing the percentage of deaths before first discharge over 28 days since randomization between placebo and Clopidogrel groups. The graph shows cumulative death percentages with labels indicating deaths and corresponding percentages for placebo (1845 deaths, 8.1%) and Clopidogrel (1726 deaths, 7.5%), noting a 7% proportional risk reduction (p = 0.03). The x-axis represents days since randomization and the y-axis shows percentage dead before discharge.*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 05)

A line graph comparing the percentage of patients experiencing death, reinfarction, or stroke before first discharge over 28 days between placebo and clopidogrel groups. The graph shows a 9% proportional risk reduction with clopidogrel compared to placebo, with event rates of 10.1% for placebo and 9.2% for clopidogrel.*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 06)

A forest plot showing event percentages for Clopidogrel (22,961 participants) versus placebo (22,891 participants) across various baseline categories such as sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent given, prognostic index, and metoprolol allocation. It includes odds ratios with confidence intervals and heterogeneity test results, illustrating a proportional reduction with Clopidogrel of 9% (p = 0.002).*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 07)

This is a forest plot chart showing an odds ratio comparison between Clopidogrel and placebo across different clinical subgroups categorized by Killip class, previous myocardial infarction status, and infarct location. The chart presents event rates (%) for each group, confidence intervals, and p-values for heterogeneity tests, indicating a proportional reduction with Clopidogrel overall.*

FDA Label Image

Figure (1086a7b4 B89b 4bee 8120 5f752626c046 08)

A cumulative event rate line graph comparing fatal or non-fatal vascular events over 36 months of follow-up for Aspirin and Plavix. The vertical axis shows cumulative event rate percentage from 0 to 16, and the horizontal axis shows months of follow-up from 0 to 36. Plavix shows a slightly lower event rate than Aspirin over time, with a p-value of 0.045 noted on the chart.*

FDA Label Image

Plavix 75 mg (1086a7b4 B89b 4bee 8120 5f752626c046 09)

Plavix 75mg tablets label showing a package of 90 tablets. The label states each tablet contains 97.875mg of Clopidogrel Bisulfate equivalent to 75mg of Clopidogrel base. Distributed by Physician Partner, with manufacturing credited to Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Includes storage instructions and product ID RP066590.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.